近期,医药生物板块在资本市场上表现出强劲的“吸金”能力,市场情绪显著回暖。数据显示,截至1月30日,科创创新药ETF国泰已连续10个交易日获得资金净申购,区间净流入额达到6.67亿元。这一资金流向的背后,是行业基本面与政策面的双重共振。1月下旬,行业内并购重组与海外授权消息频传,例如中国生物制药宣布以12亿元全资收购赫吉亚生物,以及荣昌生物与艾伯维达成高达6.5亿美元首付款的独家授权协议。这些重磅...
Source Link近期,医药生物板块在资本市场上表现出强劲的“吸金”能力,市场情绪显著回暖。数据显示,截至1月30日,科创创新药ETF国泰已连续10个交易日获得资金净申购,区间净流入额达到6.67亿元。这一资金流向的背后,是行业基本面与政策面的双重共振。1月下旬,行业内并购重组与海外授权消息频传,例如中国生物制药宣布以12亿元全资收购赫吉亚生物,以及荣昌生物与艾伯维达成高达6.5亿美元首付款的独家授权协议。这些重磅...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.